Fig. 2

Progression-free survival. A Patients were maintained with chemotherapy or targeted drugs. Latter elicited more PFS improvement (P < 0.0001, log-rank tests). B Patients with adenocarcinomas or squamous NSCLC did not significantly differ (P = 0.230, log-rank tests). MT, maintenance treatment; NSCLC, non-small cell lung cancer; PFS, progression-free survival